Trifiletti A, Scamardi R, Pizzoleo M A, Nevoso A, Soraci S, Bartolone S, Bagnato L, Barbera N
Chair of Angiology, University of Messina, Italy.
Panminerva Med. 1997 Sep;39(3):202-4.
The aim of this study was to investigate the haemostatic effects of iloprost, a stable analogue of prostacyclin, in patients with peripheral arterial disease. In a group of 13 patients with obliterative arteriopathies of the lower limbs the plasma levels of thrombomodulin (TM), betathromboglobulin (beta-TG), D-dimer (DD) and plasminogen activator-inhibitor (pAI-1) were measured, and compared to the values obtained from 10 healthy volunteers. All the parameters were found to be significantly higher in vasculopathic patients. These haemostatic evaluations were carried out after 4 weeks of treatment with iloprost up to 2 ng/kg/min, 6 hours infusion per day. During and at the end of treatment a clinical improvement was recorded. The patients also showed a significant decrease in plasma beta-TG and DD at the end of treatment. These data suggest that iloprost exerts clinical improvement, in who may have a part the decrease of platelet activation and of fibrin turnover.
本研究的目的是调查前列环素的稳定类似物伊洛前列素对周围动脉疾病患者的止血作用。在一组13例下肢闭塞性动脉病患者中，测量了血栓调节蛋白（TM）、β-血小板球蛋白（β-TG）、D-二聚体（DD）和纤溶酶原激活物抑制剂（pAI-1）的血浆水平，并与10名健康志愿者的测量值进行比较。发现血管病变患者的所有参数均显著更高。在用伊洛前列素以高达2 ng/kg/min的剂量、每天输注6小时治疗4周后，进行了这些止血评估。在治疗期间和结束时记录到临床改善。患者在治疗结束时血浆β-TG和DD也显著降低。这些数据表明，伊洛前列素可带来临床改善，血小板活化和纤维蛋白周转的降低可能起到了一定作用。
